MARKET

EIDX

EIDX

Eidos Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

73.29
-0.71
-0.96%
After Hours: 73.29 0 0.00% 16:00 10/23 EDT
OPEN
74.64
PREV CLOSE
74.00
HIGH
75.32
LOW
72.31
VOLUME
625.11K
TURNOVER
--
52 WEEK HIGH
76.94
52 WEEK LOW
28.39
MARKET CAP
2.83B
P/E (TTM)
-43.6978
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: Eidos Therapeutics, Inc. (Nasdaq - EIDX), BioSpecifics Technologies Corp. (NasdaqGS - BSTC), Front Yard Residential Corporation (NYSE - RESI)
BALA CYNWYD, PA / ACCESSWIRE / October 21, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions.
ACCESSWIRE · 2d ago
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, NY / ACCESSWIRE / October 20, 2020 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:Eidos Therapeutics, Inc.
ACCESSWIRE · 3d ago
The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 19)
Benzinga · 3d ago
The Daily Biotech Pulse: Patent Award For Theratechnologies, Enzo Biochem's Q4, Codiak Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 13)
Benzinga · 10/14 11:53
EIDX INVESTOR ALERT - Andrews & Springer LLC Is Investigating Eidos Therapeutics, Inc. For Potential Breaches of Fiduciary Duty
WILMINGTON, DE / ACCESSWIRE / October 13, 2020 / Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Eidos Therapeutics, Inc.
ACCESSWIRE · 10/13 12:03
Merger Arbitrage Mondays - Bristol Myers Squibb And Morgan Stanley Are Back At It
Merger activity decreased last week with four new deals announced.The acquisition of MyoKardia by Bristol Myers Squibb Company.The acquisition of Eaton Vance by Morgan Stanley.
Seekingalpha · 10/12 13:09
EIDOS MERGER INVESTIGTION ALERT - Andrews & Springer LLC Is Seeking More Cash for Shareholders of Eidos Therapeutics, Inc. - EIDX
WILMINGTON, Del., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Eidos Therapeutics, Inc. (NASDAQ: EIDX) (“Eidos” or the “Company”) relating to the sale of the Company to BridgeBio Pharma, Inc. (“BridgeBio”), which owns and controls over 63% of Eidos. The two parties have announced that they reached an agreement in principle pursuant to which BridgeBio will acquire Eidos. As a result of the merger, Eidos shareholders are only anticipated to receive either 1.85 shares of BridgeBio common stock or $73.26 per share in cash in exchange for each share of Eidos. Andrews & Springer’s investigation so far has revealed that the consideration Eidos shareholders are expected to receive is inadequate. Our Firm's investigation so far has discovered that the process leading up to the announcement of the merger appears to have significant conflicts of interest, thus making the process and consideration unfair. Andrews & Springer is also investigating whether the Eidos directors breached their fiduciary duties by failing to adequately shop the company and maximize shareholder value.If you own shares of Eidos and want to receive additional information and protect your investments free of charge, please visit us at https://www.andrewsspringer.com/cases-investigations/eidos-merger-class-action-investigation/ or contact Craig J. Springer, Esq. at cspringer@andrewsspringer.com, or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – www.linkedin.com/company/andrews-&-springer-llc, Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.Contact:         Craig J. Springer, Esq. cspringer@andrewsspringer.com Toll Free: 1-800-423-6013
GlobeNewswire · 10/09 23:23
The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7)
Benzinga · 10/08 11:52
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EIDX. Analyze the recent business situations of Eidos Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EIDX stock price target is 62.82 with a high estimate of 80.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 145
Institutional Holdings: 14.55M
% Owned: 37.70%
Shares Outstanding: 38.59M
TypeInstitutionsShares
Increased
29
665.20K
New
35
62.83K
Decreased
24
836.88K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.72%
Pharmaceuticals & Medical Research
+0.77%
Key Executives
President
Jonathan Fox
Chief Executive Officer/Director
Neil Kumar
Chief Scientific Officer/Director
Uma Sinha
Senior Vice President - Finance/Chief Accounting Officer
Franco Valle
Other
Cameron Turtle
Independent Director
Suzanne Hooper
Independent Director
William Lis
Independent Director
Douglas Rohlen
Independent Director
Ali Satvat
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EIDX
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company’s product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Eidos Therapeutics Inc stock information, including NASDAQ:EIDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EIDX stock methods without spending real money on the virtual paper trading platform.